BioAtla, Inc.
BioAtla, Inc.（BCAB）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · BCAB · 截至 2025年9月30日
股东结构概览
45
机构持有人数
▲ 5 vs Q2
$9.19M
机构持仓总市值
▲ $3.98M vs Q2
1.26M
总流通股
freeFloat 84.85%
13.35M
13F 申报持股数
▲ 180,111 vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
BCAB 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
ACORN CAPITAL ADVISORS, LLC biological products, (no diagnostic substances) | 4.84M | 8.26% | 8.26% | $3.34B | Nov 17, 2025 | — held |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 1.95M | 3.33% | 3.33% | $1.34B | Nov 7, 2025 | ▲ 162.6K |
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 1.37M | 2.35% | 2.35% | $945.23M | Nov 14, 2025 | — held |
ACADIAN ASSET MANAGEMENT LLC biological products, (no diagnostic substances) | 930.5K | 1.59% | 1.59% | $638.00M | Nov 13, 2025 | ▼ 562.1K |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 800.6K | 1.37% | 1.37% | $550.75M | Nov 13, 2025 | ▲ 46.4K |
DEUTSCHE BANK AG\ biological products, (no diagnostic substances) | 525.4K | 89.80% | 89.80% | $362.49M | Nov 13, 2025 | — held |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 495.2K | 84.65% | 84.65% | $340.73M | Nov 12, 2025 | ▲ 3.0K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 480.9K | 82.20% | 82.20% | $330.83M | Nov 12, 2025 | — held |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 341.3K | 58.34% | 58.34% | $234.79M | Nov 14, 2025 | ▲ 341.3K |
CITADEL ADVISORS LLC biological products, (no diagnostic substances) | 274.0K | 46.84% | 46.84% | $188.51M | Nov 14, 2025 | NEW |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
14
增持
+1.03M 股9
新建仓
首次建仓5
减持
−913.5K 股5
清仓
完全退出净股数变化（前50家）
+120.2K
+1.03M / −913.5K
净新增持仓人
+13
新建 9 个 / 退出 5 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
BCAB 内幕交易记录
数据来源：SEC Form 4
3
买入笔数
4
卖出笔数
0.75
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Vasquez Christian Chief Financial Officer | Mar 11, 2026 | Tax Withhold | 175 | $0.17 | $29.575 | 10.4K | Form 4 ↗ |
Vasquez Christian Chief Financial Officer | May 31, 2026 | Tax Withhold | 82 | $3.93 | $322.26 | 10.3K | Form 4 ↗ |
SHORT JAY M PHD Chief Executive Officer | Mar 12, 2026 | Tax Withhold | 639 | $0.17 | $107.352 | 52.6K | Form 4 ↗ |
SHORT JAY M PHD Chief Executive Officer | May 31, 2026 | Tax Withhold | 259 | $3.93 | $1.0K | 52.3K | Form 4 ↗ |
Sievers Eric Chief Medical Officer | May 31, 2026 | Tax Withhold | 134 | $3.93 | $526.62 | 11.8K | Form 4 ↗ |
Sievers Eric Chief Medical Officer | Mar 11, 2026 | Tax Withhold | 360 | $0.17 | $60.84 | 11.6K | Form 4 ↗ |
Sievers Eric Chief Medical Officer | Mar 10, 2026 | Award | 240,000 | — | — | 598.7K | Form 4 ↗ |
SHORT JAY M PHD Chief Executive Officer | Mar 11, 2026 | Award | 430,000 | — | — | 2.66M | Form 4 ↗ |
Vasquez Christian Chief Financial Officer | Mar 10, 2026 | Award | 240,000 | — | — | 530.2K | Form 4 ↗ |
SHORT JAY M PHD Chief Executive Officer | Feb 28, 2026 | Tax Withhold | 7,728 | $0.25 | $1.9K | 2.23M | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
BioAtla, Inc.（BCAB）主要由机构投资者持有，机构持股比例约为 100.0%。公司内部人员持股约 15.15%，散户及公众持股约占剩余的 0.00%。
BioAtla, Inc. 最大机构股东为 ACORN CAPITAL ADVISORS, LLC，截至 September 30, 2025 持有约 4.84 million 股，占总流通股的 8.26%。
目前共有 45 家机构持有 BCAB 股票，合计持仓市值约 $9,190,012，数据来源为最新 SEC 13F 申报。
常见问题
BCAB ownershipBioAtla, Inc.（BCAB）主要由机构投资者持有，机构持股约 100.0%。最大股东为 ACORN CAPITAL ADVISORS, LLC，持股比例 8.26%。内部人员持股约 15.15%。数据来源 SEC Form 13F，截至 September 30, 2025。